Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
Patients, 18 years and older, who meet the following criteria:
Kim Reiss-Binder, MD
University of Pennsylvania
The LODESTAR study is evaluating the response of the PARP inhibitor rucaparib in people with advanced solid tumors (including breast, ovarian, pancreatic, prostate and other cancers) who have an inherited mutation or an acquired mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.
This study is a Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in patients with various solid tumors who also have specific genetic mutations.
Kim Reiss-Binder, MD, University of Pennsylvania